1/20
10:26 am
rxrx
Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory [Yahoo! Finance]
1/18
12:41 pm
rxrx
JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment Prospects [Yahoo! Finance]
Medium
Report
JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment Prospects [Yahoo! Finance]
1/16
10:38 pm
rxrx
Is Recursion Pharmaceuticals (RXRX) Pricing In Its AI Drug Discovery Ambitions? [Yahoo! Finance]
Medium
Report
Is Recursion Pharmaceuticals (RXRX) Pricing In Its AI Drug Discovery Ambitions? [Yahoo! Finance]
1/15
08:09 pm
rxrx
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note [Yahoo! Finance]
1/9
06:11 am
rxrx
Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know [Yahoo! Finance]
1/7
08:31 pm
rxrx
Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates [Yahoo! Finance]
1/7
03:41 pm
rxrx
Lux Capital lands $1.5 billion for its largest fund ever [Yahoo! Finance]
Low
Report
Lux Capital lands $1.5 billion for its largest fund ever [Yahoo! Finance]
1/7
03:18 pm
rxrx
Lux Capital lands $1.5 billion for its largest fund ever [TechCrunch]
Low
Report
Lux Capital lands $1.5 billion for its largest fund ever [TechCrunch]
1/6
07:59 am
rxrx
Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference
1/2
09:29 am
rxrx
JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline [Yahoo! Finance]
Low
Report
JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline [Yahoo! Finance]
1/1
08:00 am
rxrx
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. [Yahoo! Finance]
Low
Report
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. [Yahoo! Finance]
1/1
07:15 am
rxrx
Cathie Wood's ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) [Yahoo! Finance]
Low
Report
Cathie Wood's ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) [Yahoo! Finance]
12/29
12:11 pm
rxrx
Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP [Yahoo! Finance]
Neutral
Report
Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP [Yahoo! Finance]
12/28
12:57 pm
rxrx
Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform [Yahoo! Finance]
12/24
12:08 pm
rxrx
Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? [Yahoo! Finance]
Low
Report
Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? [Yahoo! Finance]
12/22
10:34 am
rxrx
How Investors May Respond To Recursion Pharmaceuticals (RXRX) Early FAP Trial Success And AI Platform Validation [Yahoo! Finance]
Low
Report
How Investors May Respond To Recursion Pharmaceuticals (RXRX) Early FAP Trial Success And AI Platform Validation [Yahoo! Finance]
12/21
05:16 pm
rxrx
Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades [Yahoo! Finance]
12/21
07:51 am
rxrx
Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? [Yahoo! Finance]
Low
Report
Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? [Yahoo! Finance]
12/18
11:39 am
rxrx
Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 [Seeking Alpha]
Medium
Report
Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 [Seeking Alpha]
12/17
08:45 am
rxrx
Recursion Pharmaceuticals (NASDAQ:RXRX) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $11.00 price target on the stock, up previously from $10.00.
Medium
Report
Recursion Pharmaceuticals (NASDAQ:RXRX) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $11.00 price target on the stock, up previously from $10.00.
12/17
05:10 am
rxrx
Recursion Pharmaceuticals (NASDAQ:RXRX) was given a new $11.00 price target on by analysts at UBS Group AG.
Medium
Report
Recursion Pharmaceuticals (NASDAQ:RXRX) was given a new $11.00 price target on by analysts at UBS Group AG.
12/17
05:10 am
rxrx
Recursion Pharmaceuticals (NASDAQ:RXRX) was given a new $11.00 price target on by analysts at Morgan Stanley.
Medium
Report
Recursion Pharmaceuticals (NASDAQ:RXRX) was given a new $11.00 price target on by analysts at Morgan Stanley.
12/10
02:58 pm
rxrx
Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment [Seeking Alpha]
Low
Report
Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment [Seeking Alpha]
12/8
07:30 am
rxrx
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
Low
Report
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
12/5
07:03 pm
rxrx
Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]
Low
Report
Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]